Loading...
Loading...
BNTC| Name | Value |
|---|---|
| Revenues | 0.6M |
| Cost of Revenue | 0.3M |
| Gross Profit | 0.3M |
| Operating Expense | 17.2M |
| Operating I/L | -17.2M |
| Other Income/Expense | 1.0M |
| Interest Income | 2.2M |
| Pretax | -16.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -16.1M |
Benitec Biopharma Inc. is a biotechnology company specializing in the development of DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. The company's main focus is on developing gene therapy agents such as BB-301 for treating oculopharyngeal muscular dystrophy and BB-103 for chronic hepatitis B virus infection.
